Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Key design requirements include room-temperature flowability, fast gelation at physiological temperature, and network integrity under synovial dilution and mechanical loading
Funding The work was supported by Natural Science Foundation of Liaoning Province (2019-MS-075), Liaoning Revitalization Talents Program (XLYC1807124), Dalian Technology Innovation Program (2019J13SN109) and Health Commission of Dalian (1811014)
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
No formal clinical trials have evaluated infant exposure or developmental safety from nursing mothers taking tirzepatide
In further pharmacological experiments, LUT@PPS-PEG nano-composites were effectively taken up by SK-MEL-28 cells and significantly inhibited their proliferation and migration
US$ 27.00
US$ 20.77
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 22.04
US$ 27.50
US$ 20.26
US$ 28.00
US$ 22.16
